FastWave Announces Medical Advisor Appointments and Pipeline Update

March 6, 2024—FastWave Medical Inc., a device company focused the treatment of calcified cardiovascular disease through intravascular lithotripsy (IVL), recently announced the appointments of eight medical advisors.

Additionally, the company announced the issuance of its third utility patent by the US Patent and Trademark Office that supports the differentiated design of FastWave’s next-generation IVL system, which aims to address challenges associated with treating calcified arteries in patients with occlusive vascular disease.

According to FastWave Medical, the newly appointed medical advisors will be pivotal in moving the company’s coronary and peripheral IVL systems through the stages of product development and clinical trials.

Appointments to FastWave’s medical advisory team include:

• Farouc Jaffer, MD, from Massachusetts General Hospital and Harvard Medical School in Boston, Massachusetts
• Amir Kaki, MD, from St. John’s Medical Center in Detroit, Michigan
• Kathleen Kearney MD, from University of Washington in Seattle, Washington
• Arthur Lee, MD, from The Cardiac & Vascular Institute in Gainesville, Florida
• Miguel Montero-Baker, MD, from HOPE Vascular and Podiatry in Houston, Texas
• William Nicholson, MD, from Emory Healthcare in Atlanta, Georgia
• Peter Schneider, MD, from University of California San Francisco in San Francisco, California
• Venkatesh Ramaiah, MD, from Pulse Cardiovascular and HonorHealth in Scottsdale, Arizona

“We continue to encounter coronary and peripheral disease complicated by severe calcium, presenting a significant therapeutic challenge when employing interventional tools,” commented Dr. Kaki in the company’s press release. “Intravascular lithotripsy has emerged as an effective and transformative modality, capable of modifying calcium and facilitating an optimal mechanical outcome when successfully delivered to the diseased artery. I am eager to collaborate with my fellow advisors to advance FastWave’s IVL platforms, which hold the potential to enhance deliverability and ensure more consistent sonic output, thus enabling a greater number of patients to benefit from IVL treatment.”

Addressing the newly issued patent, Dr. Jaffer commented in the press release, “The issuance of FastWave’s third utility patent is a testament to the phenomenal work being done by their experienced team. This milestone further validates the strength and novelty of the company’s technology, which has the potential to positively impact patient outcomes.”